The role of tumour microenvironment in gastric cancer angiogenesis

Brzozowa, Marlena; Michalski, Marek; Harabin-Słowińska, Marzena; Wojnicz, Romuald

doi:10.5114/pg.2014.47894

Cited by 8 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite advances in development of surgical therapy for gastric cancer (GC) and improvement in early diagnosis, the prognosis of metastatic GC is still poor, with a 5-year survival rate about only 3.1% in advanced GC patients [14]. Since most GC patients are diagnosed when the tumor is at an unresectable stage, early diagnosis of GC is crucial for treatment [15]. Studies showed that the NOB1 gene was associated with tumor development in various cancers such as ovarian cancer [16], laryngeal cancer [17], lung cancer [18], colorectal cancer [19], and gastric cancer [20] and could be a potential biomarker in predicting prognosis of lung cancer outcomes [18,21].…”

Section: Discussionmentioning

confidence: 99%

NOB1 Gene as a Potential Biomarker in Clinical Outcomes and Prognosis of Patients with Gastric Cancer

Qin¹,

Ya²

2018

Clin. Lab.

View full text Add to dashboard Cite

Background: To investigate relationship of the Nin one binding protein (NOB1) gene with the prognosis of gastric cancer (GC). Methods: The GC tumor tissues and paired adjacent normal gastric tissues were collected from 65 patients who underwent primary gastric resection surgery in our hospital from January 2009 to July 2011. Data including age, gender, family cancer history, tumor diameter, pathological type, differentiation, clinical stage by tumor node metastasis (TNM) staging, lymphatic metastasis, and distant metastasis were collected. Expression of NOB1 and VEGF was determined using real time PCR. The relationship of NOB1 with clinical outcomes and prognosis of GC patients was analyzed by statistical methods. Results: Both mRNA expression of NOB1 and VEGF was significantly higher in tumor tissues than that of the normal tissues, p < 0.05, and mRNA expression of NOB1 was positively correlated with mRNA expression of VEGF by Pearson's correlation analysis. Significant difference was observed in TNM stage, tumor differentiation, and metastasis between the low and high NOB1 expression groups, p < 0.05, while no significant difference was observed in age, gender, family cancer history, tumor location, and diameter. Univariate analysis showed that TNM stage, tumor differentiation, lymphatic metastasis, distant metastasis and expression of NOB1 and VEGF were all significantly different in survival and dead patients. Logistic analysis showed that NOB1 was an independent risk factor for 5-year mortality of GC patients, as well as lymphatic metastasis and distant metastasis. Conclusions: NOB1 was correlated with clinical outcomes and prognosis of GC patients and was an independent risk factor for 5-year mortality of GC patients. This study might provide more clinical evidences for NOB1 in GC and give a new target for diagnosis and treatment for GC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

NOB1 Gene as a Potential Biomarker in Clinical Outcomes and Prognosis of Patients with Gastric Cancer

Qin¹,

Ya²

2018

Clin. Lab.

View full text Add to dashboard Cite

show abstract

“…Lymph node status is an independent prognostic factor in gastric cancer almost regardless of the staging method. But there are other prognostic factors such as T stage, M stage, vascular involvement, and histologic type of the tumour [ 26 , 27 ]. N status is also related to other factors because different incidences of LN metastases are observed in different T stages [ 27 ].…”

Section: Metastatic Lymph Nodes Are Not Independentmentioning

confidence: 99%

“…But there are other prognostic factors such as T stage, M stage, vascular involvement, and histologic type of the tumour [ 26 , 27 ]. N status is also related to other factors because different incidences of LN metastases are observed in different T stages [ 27 ]. On the other hand, metastasis to the specific LN stations may be correlated with the poor prognosis [ 28 ].…”

Section: Metastatic Lymph Nodes Are Not Independentmentioning

confidence: 99%

Alternative staging of regional lymph nodes in gastric cancer

Szczepanik

Paszko

Szura

et al. 2016

View full text Add to dashboard Cite

The TNM pN stage based on the number of metastatic lymph nodes is an independent prognostic factor in gastric cancer. Many studies have highlighted the phenomenon of stage migration and problems in comparing groups of patients with different numbers of total lymph nodes harvested within TNM staging. The current version of UICC/AJCC and JGCA TNM classifications postulates a minimal number of 16 lymph nodes as the base for N stage determination. Alternative systems such as lymph node ratio (LNR), positive to negative lymph node ratio (PNLNR), and LOGODDS (or LODDS), were implemented to increase the quality of LN assessment. These methods have reached the background in the literature, but to date no standard approach according to the cut-offs for the stages has been implemented. LOGODDS is the method that most reflects the number of harvested lymph nodes. The rationale for alternative staging methods, their correlations, and limitations are presented.

show abstract

“…In preclinical models, anti-VEGF/VEGF receptor therapies show potent inhibition of angiogenesis and tumor growth [ 5 ]. In patients with gastric cancer, high VEGF levels are associated with increased tumor aggressiveness and reduced survival [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

Gil-Delgado

Lucidarme

Bachet

et al. 2018

Case Rep Gastroenterol

View full text Add to dashboard Cite

We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m² intravenously (days 1, 8, 15), every 4 weeks in patients with previously treated advanced gastroesophageal junction adenocarcinoma. A 64-year-old man with gastroesophageal junction adenocarcinoma and liver metastases received first-line folinic acid, 5-fluorouracil plus oxaliplatin (FOLFOX) following jejunostomy. On liver progression, he enrolled in RAINBOW (April 2012), receiving ramucirumab. In November 2013, positron emission tomography scan was consistent with complete metabolic response, confirmed by a follow-up scan in March 2016.

show abstract

The role of tumour microenvironment in gastric cancer angiogenesis

Cited by 8 publications

References 28 publications

NOB1 Gene as a Potential Biomarker in Clinical Outcomes and Prognosis of Patients with Gastric Cancer

NOB1 Gene as a Potential Biomarker in Clinical Outcomes and Prognosis of Patients with Gastric Cancer

Alternative staging of regional lymph nodes in gastric cancer

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

Contact Info

Product

Resources

About